Polyethylene Glycol 400
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Polyethylene Glycol 400: From Constipation and Dry Eye to Bronchitis
One-Sentence Summary
Polyethylene glycol 400 (PEG 400) was originally used for constipation and dry eye conditions (dry eye syndrome, xerophthalmia). The TxGNN model predicts it may be effective for bronchitis, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation disorder, dry eye syndrome, xerophthalmia (the Canadian licence records contain no indication text) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9958 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, PEG 400 is a lubricating, hydrating polymer. It is used as an eye-drop ingredient, and its original indications (constipation and dry eye) both relate to moisture retention and lubrication.
A speculative link to bronchitis may exist if these osmotic, hydrating and lubricating properties could affect airway mucus hydration. This is a hypothesis only and is not supported by the data compiled for this report. PEG 400 is mainly used as a pharmaceutical excipient or lubricant, and there is no evidence that it has therapeutic activity against respiratory tract inflammation or infection. The high TxGNN score is a model output and should not be read as clinical evidence.
A second prediction, congenital ichthyosiform erythroderma (score 0.9910), also has no supporting trials or literature. Its rationale is limited to the moisturizing properties of PEG 400, which would at most provide symptomatic skin hydration and would not modify a genetic keratinization disorder.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02518228 | RED EYE WORKPLACE | Not specified | Not specified |
| 02518201 | RED EYE TRIPLE ACTION | Not specified | Not specified |
| 02344319 | ADVANCED RELIEF EYE DROPS | Not specified | Not specified |
All three licences are valid products, and all are eye-care products. This route differs from the airway route that bronchitis would require, and route compatibility has not been assessed.
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.
- Contraindications in the knowledge graph (not label text): The TxGNN knowledge graph links PEG 400 to a number of contraindicated conditions. These include:
- Cardiovascular: hypertension, congestive heart failure, cardiovascular disease
- Renal and metabolic: kidney disease, anuria, hypercalcemia, nephrocalcinosis, hyperglycemia, diabetes mellitus, diabetic ketoacidosis, potassium deficiency, phosphorus metabolism disease
- Gastrointestinal: ileus, intestinal obstruction, paralytic ileus, toxic megacolon, pyloric stenosis, appendicitis, familial visceral myopathy
- Eye: angle-closure glaucoma, conjunctivitis, eye infectious disease
- Other: epilepsy, hyperthyroidism, Graves disease, thyrotoxicosis, pyoureter
These come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. They need verification against actual labelling.
- Drug interactions: No interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for bronchitis is supported only by a model score (Evidence Level L5). There are no clinical trials or publications, the mechanistic link is speculative, and PEG 400 is mainly an excipient or lubricant with no known therapeutic activity in the airways. The safety data are also incomplete.
To proceed, the following is needed:
- Mechanism of action data (for example, from DrugBank)
- Health Canada package insert warnings and contraindications, to allow safety screening
- A literature and trial search on PEG 400 and airway mucus hydration or respiratory disease
- An assessment of route compatibility, since current Canadian products are ophthalmic
- Verification of the knowledge-graph contraindications against actual labelling
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.